Safety and efficacy of trastuzumab administered as a 30-min infusion in patients with HER2-positive advanced gastric cancer.

Sung Yong OhSuee LeeSeok Jae HuhJeeyun LeeSeung Tae KimSe Hoon ParkHo Yeong LimWon Ki KangByung Woog KangJong Gwang KimHyo Jin LeeJung Hoon KimJung Hun KangHoUng Kim

Published in: Cancer chemotherapy and pharmacology (2018)

Trastuzumab 30-min maintenance infusions were well tolerated with a good safety profile, and resulted in sustained efficacy in patients with HER2-positive advanced gastric cancer.

Keyphrases

neoadjuvant chemotherapy
epidermal growth factor receptor
metastatic breast cancer
low dose
lymph node
radiation therapy
locally advanced